Hypoparathyroidism: New Treatment Concepts and Guidelines
Hypoparathyroidism has physical and cognitive manifestations that profoundly affect a patient’s quality of life. Until recently, the management of hypoparathyroidism was aimed at reducing symptoms by using high doses of oral calcium and active vitamin D and addressing mineral abnormalities, while basing decisions on clinical judgment and experience. The recent approval of parathyroid hormone (PTH) replacement therapy and the release of US guidelines to guide the management of hypoparathyroidism are expected to drastically change the standard management of this condition, while improving patient outcomes.
"Hypoparathyroidism: New Treatment Concepts and Guidelines" will provide guidance on the management of hypoparathyroidism to clinicians who care for patients with thyroid diseases. This activity will also explore the application of new guidelines and emerging data on clinical decision-making strategies and the selection of individualized treatment regimens for these patients.
Please Note: this course is housed on Medscape. Upon selecting 'Take Course,' you will be redirected to Medscape to compete the activity.
This activity is intended for clinical endocrinologists and other healthcare professionals who are committed to learning about the latest advances in endocrinology research and applying new findings to the evidence-based care of patients with hormone disorders.
Upon completion of this activity, participants will be able to:
- Integrate the most recent understanding about the burden of disease of hypoparathyroidism, its diagnosis, and clinical presentation
- Summarize the benefits and challenges with calcium and vitamin D therapy
- Evaluate the role of replacement therapy with parathyroid hormone
- Integrate new guidelines on the management of hypoparathyroidism
John Bilezikian, MD, MACE, MACP; Bart L. Clarke, MD, FACE, FACP; Steven M. Petak, MD, JD, MACE, FACP
- 1.25 AMA
- 1.25 Attendance